Parkinson’s Disease Epidemiology Forecast Report 2019-2023 and 2023-2032: Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan – ResearchAndMarkets.com

Parkinson’s Disease Epidemiology Forecast Report 2019-2023 and 2023-2032: Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan – ResearchAndMarkets.com




Parkinson’s Disease Epidemiology Forecast Report 2019-2023 and 2023-2032: Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Parkinson’s Disease – Epidemiology Forecast – 2032” report has been added to ResearchAndMarkets.com’s offering.


This report delivers an in-depth understanding of Parkinson’s disease, historical and forecasted epidemiology, as well as the trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Parkinson’s Disease Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of Parkinson’s disease, gender-specific diagnosed prevalent cases of Parkinson’s disease, age-specific diagnosed prevalent cases of Parkinson’s disease, and stage-specific diagnosed prevalent cases of Parkinson’s disease in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

Parkinson’s Disease Detailed Epidemiology Segmentation

  • In 2022, there were approximately 2,539,400 diagnosed prevalent cases of Parkinson’s disease in the 7MM. The US accounted for nearly 45% of the total diagnosed prevalent cases of Parkinson’s disease in the 7MM.
  • The publisher’s epidemiology model for Parkinson’s disease estimates that in the US, nearly 660,458 cases and 491,736 cases were contributed by males and females, respectively, in 2022. These cases are expected to increase by 2032, with the disease being more prevalent in males than females.
  • As per the report estimates, in 2022, in the US, approximately 18,870 cases were diagnosed with Parkinson’s disease in the age group =49 years, nearly 204,243 cases in 50-64 years, around 427,355 cases in 65-74 years, and approximately 501,726 cases in =75 years. By 2032, the cases in different age groups are expected to increase.
  • Among EU4 and the UK, there were approximately 1,185,570 diagnosed prevalent cases of Parkinson’s disease. Germany accounted for the highest number of Parkinson’s disease cases, with nearly 454,448 cases, while Italy accounted for the least diagnosed prevalent cases of Parkinson’s disease in 2022.
  • In 2022, in EU4 and the UK, the highest diagnosed prevalent cases of Parkinson’s were found in Stage II with approximately 388,499 cases, followed by Stage III with nearly 384,960 cases, Stage IV with around 208,042 cases, Stage I with nearly 153,164 cases, and Stage V with approximately 50,904 cases, The stage-specific diagnosed prevalent cases of Parkinson’s disease are expected to change by 2032.
  • In 2022, among the 7MM, Japan accounted for nearly 8% of the diagnosed prevalent cases of Parkinson’s disease. The cases are estimated to increase during the forecast period.
  • In Japan, males diagnosed with Parkinson’s disease are higher in number than females. In 2022, there were approximately 105,583 male cases, while around 96,053 cases were among the female population.

Scope of the Report

  • The report covers a descriptive overview of Parkinson’s disease, explaining its symptoms, pathophysiology, and various diagnostic approaches.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
  • The report assesses the disease risk and burden of Parkinson’s disease.
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population.
  • The report provides the segmentation of the disease epidemiology for the 7MM, the total diagnosed prevalent cases of Parkinson’s disease, gender-specific diagnosed prevalent cases of Parkinson’s disease, age-specific diagnosed prevalent cases of Parkinson’s disease, and stage-specific diagnosed prevalent cases of Parkinson’s disease.

Report Highlights

  • Ten years forecast of Parkinson’s disease
  • The 7MM Coverage
  • Total Diagnosed Prevalent Cases of Parkinson’s disease
  • Gender-specific Diagnosed Prevalent Cases of Parkinson’s disease
  • Age-specific Diagnosed Prevalent Cases of Parkinson’s disease
  • Stage-specific Diagnosed Prevalent Cases of Parkinson’s disease

Key Questions Answered

  • What are the disease risks and burdens of Parkinson’s disease?
  • What is the historical Parkinson’s disease patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
  • What would be the forecasted patient pool of Parkinson’s disease at the 7MM level?
  • What growth opportunities will be across the 7MM concerning the patient population with Parkinson’s disease?
  • Which country would have the highest diagnosed prevalent population of Parkinson’s disease among the countries mentioned above during the forecast period (2023-2032)?
  • At what CAGR is the population expected to grow across the 7MM during the forecast period (2023-2032)?

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of Disease by Segmentation
  • Factors Driving Growth in a Specific Patient Population

For more information about this report visit https://www.researchandmarkets.com/r/evj8jg

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900